Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25725323 | 0.91 | PDK2 (0.41) | PDK2LTB4RLTB4R2L3MBTL1EGFR | |
| SCHEMBL24344772 | 0.89 | FFAR4 (0.42) | PDK2LTB4RLTB4R2L3MBTL1EGFR | |
| SCHEMBL26691734 | 0.85 | L3MBTL1 (0.42) | PDK2HIF1AMEN1KMT2AL3MBTL1 | |
| Bromide SCHEMBL30195582 | 0.83 | L3MBTL1 (0.39) | PDK2HIF1AL3MBTL1HTR2CSLC6A4 | |
| SCHEMBL25725295 | 0.79 | GBA1 (0.46) | PDK2MEN1KMT2AL3MBTL1HTR2C | |
| SCHEMBL26691721 | 0.79 | KDM4E (0.40) | PDK2KMT2AACHEKDM4ELMNA | |
| SCHEMBL7646792 | 0.78 | HTR1A (0.51) | LTB4RLTB4R2L3MBTL1 | |
| SCHEMBL3014165 | 0.78 | LTB4R (0.67) | LTB4RLTB4R2EGFRALOX5 | |
| SCHEMBL26691712 | 0.77 | PDK2 (0.42) | PDK2EGFRACHE | |
| SCHEMBL4454375 | 0.77 | FFAR1 (0.59) | LTB4RLTB4R2MEN1KMT2AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373813-A1 | COMPOUNDS AND METHODS FOR DETECTION OF SUPEROXIDE | PROMEGA CORPORATION (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11802114-B2 | Compounds and methods for detection of superoxide | PROMEGA CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2023004046-A1 | COMPOUNDS AND METHODS FOR DETECTION OF SUPEROXIDE | PROMEGA CORPORATION (US) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802114-B2 | Compounds and methods for detection of superoxide | SOD1, GPX4, SOD3 | PDK2 487/4885LTB4R 1459/4885LTB4R2 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.